HepaTx Corporation is developing regenerative medicine solutions to address the need for better therapies for life-threatening liver diseases. Anchored in work undertaken at, and patented by Stanford University, the firm's approach is to enable efficient hepatocyte production for therapeutic purposes. Hepatx Corporation's therapeutics can replace lost liver function to treat those with end-stage of liver disease, potentially saving the cost and morbidity of whole organ transplant.
